Bowel Cancer Australia is very excited to announce that we have been nominated for the best small charity of the year in the Third Sector Awards 2019, celebrating Australia’s most notable leaders and organisations that are making a difference.
Nominees have been selected based on their social impact, outcomes, collaboration, and leadership.
We need your help to win!
Sam Fitzpatrick just finished 18-months of grueling treatment sessions following a Stage IV bowel cancer diagnosis at the age of 33.
But he would tell you he’s lucky.
"I learned that there are things you can control and things that you can't," said Sam.
"If you focus only on the things that you can control, it makes the tougher times a little easier."
Overcoming the misconceptions often associated with Australia's second deadliest cancer has always been a major focus of Bowel Cancer Awareness Month, an annual Bowel Cancer Australia initiative that runs throughout the month of June to raise public awareness of a disease that claims the lives of 103 Australians every week.
We strive for visible and impactful media coverage to get the message out, and our media analysis of the Bowel Cancer Awareness Month 2019 campaign indicates that’s exactly what we got.
Bowel Cancer Australia today released initial findings from the first national My Colonoscopy Experience questionnaire.
The questionnaire opened in September 2018 at the same time as the Colonoscopy Clinical Care Standard, created by the Australian Commission on Safety and Quality in Health Care (ACSQHC).
While the Standard was a welcome first step in outlining the care people who have a colonoscopy should receive, it did not contain specific indicators to measure the patient’s experience.
“Communicating the unique patient perspective is vital for understanding how to make services better and safer for patients,” said Bowel Cancer Australia CEO Julien Wiggins.
“As more and more people share their experience, findings will help shape Bowel Cancer Australia’s initiatives and can be used more broadly as a valuable resource to inform policy, programs, and investment in colonoscopy quality and care,” Mr Wiggins said.
Australia's Therapeutic Goods Administration (TGA) has today given Keytruda® (pembrolizumab) provisional approval for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) bowel cancer.